A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.


Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
10 2019
Historique:
received: 13 10 2018
revised: 13 07 2019
accepted: 07 08 2019
pubmed: 3 9 2019
medline: 17 4 2020
entrez: 3 9 2019
Statut: ppublish

Résumé

Therapeutic resistance is a major clinical challenge in oncology. Evidence identifies cancer stem cells (CSCs) as a driver of tumor evolution. Accordingly, the key stemness property unique to CSCs may represent a reservoir of therapeutic target to improve cancer treatment. Here, we carried out a genome-wide RNA interference screen to identify genes that regulate breast CSCs-fate (bCSC). Using an interactome/regulome analysis, we integrated screen results in a functional mapping of the CSC-related processes. This network analysis uncovered potential therapeutic targets controlling bCSC-fate. We tested a panel of 15 compounds targeting these regulators. We showed that mifepristone, salinomycin, and JQ1 represent the best anti-bCSC activity. A combination assay revealed a synergistic interaction of salinomycin/JQ1 association to deplete the bCSC population. Treatment of primary breast cancer xenografts with this combination reduced the tumor-initiating cell population and limited metastatic development. The clinical relevance of our findings was reinforced by an association between the expression of the bCSC-related networks and patient prognosis. Targeting bCSCs with salinomycin/JQ1 combination provides the basis for a new therapeutic approach in the treatment of breast cancer.

Identifiants

pubmed: 31476112
doi: 10.15252/emmm.201809930
pmc: PMC6783652
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e9930

Subventions

Organisme : Institut National Du Cancer (INCa)
ID : INCa_5911
Pays : International
Organisme : Institut National Du Cancer (INCa)
ID : INCa-DGOS-Inserm 6038
Pays : International
Organisme : Ligue Contre le Cancer (Label DB)
Pays : International

Informations de copyright

© 2019 The Authors. Published under the terms of the CC BY 4.0 license.

Références

BMC Genomics. 2012;13 Suppl 1:S2
pubmed: 22369666
Cell Death Dis. 2014 Feb 06;5:e1051
pubmed: 24503543
Cancer Cell. 2016 Jun 13;29(6):783-803
pubmed: 27300434
Nat Chem. 2017 Oct;9(10):1025-1033
pubmed: 28937680
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Bioinformatics. 2016 Sep 15;32(18):2866-8
pubmed: 27153664
Cell Rep. 2016 Apr 19;15(3):519-530
pubmed: 27068464
EMBO Mol Med. 2019 Oct;11(10):e9930
pubmed: 31476112
Clin Cancer Res. 2013 Nov 15;19(22):6163-72
pubmed: 24016618
Cancer Discov. 2015 Aug;5(8):806-20
pubmed: 26193902
Trends Genet. 2016 Feb;32(2):89-100
pubmed: 26689127
Cell Rep. 2017 Feb 28;18(9):2256-2268
pubmed: 28249169
Autophagy. 2013 May;9(5):714-29
pubmed: 23519090
Nat Rev Cancer. 2017 Oct;17(10):605-619
pubmed: 28912577
Cell Stem Cell. 2016 Aug 4;19(2):177-191
pubmed: 27292188
Nature. 2016 Jan 21;529(7586):413-417
pubmed: 26735014
Clin Cancer Res. 2013 Dec 1;19(23):6520-31
pubmed: 24141629
Cell. 2009 Aug 21;138(4):645-659
pubmed: 19682730
Trends Mol Med. 2015 Sep;21(9):549-59
pubmed: 26259769
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1041-6
pubmed: 23275297
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Cancer Res. 2016 Nov 1;76(21):6320-6330
pubmed: 27803105
Nat Med. 2011 Aug 28;17(9):1086-93
pubmed: 21873988
Nat Commun. 2017 Jan 19;8:14073
pubmed: 28102225
J Clin Invest. 2010 Feb;120(2):485-97
pubmed: 20051626
Science. 2015 Jan 16;347(6219):226-9
pubmed: 25593170
Cell Rep. 2015 Jan 20;10(3):383-397
pubmed: 25600873
Cancer Res. 2013 Dec 15;73(24):7290-300
pubmed: 24142344
EMBO Mol Med. 2017 May;9(5):655-671
pubmed: 28298340
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Mol Cell Biol. 2012 Apr;32(8):1483-95
pubmed: 22331469
Nature. 2015 Oct 8;526(7572):273-276
pubmed: 26416749
Cell Stem Cell. 2011 May 6;8(5):511-24
pubmed: 21419747
J Mol Biol. 2017 Jun 30;429(13):1978-1993
pubmed: 27742591
J Biomol Screen. 2003 Dec;8(6):634-47
pubmed: 14711389
Nat Med. 2014 Jan;20(1):29-36
pubmed: 24292392
PLoS One. 2017 Sep 26;12(9):e0185400
pubmed: 28949986
Cancer Res. 2009 Feb 15;69(4):1302-13
pubmed: 19190339
Autophagy. 2017 Apr 3;13(4):761-762
pubmed: 28118076
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44
pubmed: 25605917
Nat Clin Pract Oncol. 2005 Aug;2(8):416-22
pubmed: 16130938
Cell Stem Cell. 2016 Dec 1;19(6):784-799
pubmed: 27570068

Auteurs

Abir Arfaoui (A)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.
Faculté de Médecine de Tunis, LR99ES10 Laboratoire de Génétique Humaine, Université de Tunis El Manar, Tunis, Tunisia.
Service de Biologie Clinique, Institut Salah Azaiz, Tunis, Tunisia.

Claire Rioualen (C)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Plateform Integrative Bioinformatics, Cibi, Aix-Marseille Univ, Marseille, France.

Violette Azzoni (V)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Guillaume Pinna (G)

Plateforme ARN Interférence, Service de Biologie Intégrative et de Génétique Moléculaire (SBIGeM), I2BC, CEA, CNRS, Université Paris-Saclay, Gif-sur-Yvette, France.

Pascal Finetti (P)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Molecular Oncology "Equipe labellisée Ligue Contre le Cancer", Aix-Marseille Univ, Marseille, France.

Julien Wicinski (J)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Emmanuelle Josselin (E)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, TrGET Plateform, Aix-Marseille Univ, Marseille, France.

Manon Macario (M)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Rémy Castellano (R)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, TrGET Plateform, Aix-Marseille Univ, Marseille, France.

Candi Léonard-Stumpf (C)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Anthony Bal (A)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Abigaelle Gros (A)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Sylvain Lossy (S)

Plateforme ARN Interférence, Service de Biologie Intégrative et de Génétique Moléculaire (SBIGeM), I2BC, CEA, CNRS, Université Paris-Saclay, Gif-sur-Yvette, France.

Maher Kharrat (M)

Faculté de Médecine de Tunis, LR99ES10 Laboratoire de Génétique Humaine, Université de Tunis El Manar, Tunis, Tunisia.

Yves Collette (Y)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, TrGET Plateform, Aix-Marseille Univ, Marseille, France.

Francois Bertucci (F)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Molecular Oncology "Equipe labellisée Ligue Contre le Cancer", Aix-Marseille Univ, Marseille, France.

Daniel Birnbaum (D)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Molecular Oncology "Equipe labellisée Ligue Contre le Cancer", Aix-Marseille Univ, Marseille, France.

Hayet Douik (H)

Faculté de Médecine de Tunis, LR99ES10 Laboratoire de Génétique Humaine, Université de Tunis El Manar, Tunis, Tunisia.
Service de Biologie Clinique, Institut Salah Azaiz, Tunis, Tunisia.

Ghislain Bidaut (G)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Plateform Integrative Bioinformatics, Cibi, Aix-Marseille Univ, Marseille, France.

Emmanuelle Charafe-Jauffret (E)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Christophe Ginestier (C)

Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Epithelial Stem Cells and Cancer Lab, Aix-Marseille Univ, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH